Gapping up
In reaction to strong earnings/guidance/SSS: MG +16%, EXFO +9.1%, (also announces issuer bid to purchase for cancellation up to 7,142,857 subordinate voting shares for an aggregate purchase price not to exceed C$30,000,000), PIR +8.5%, CONN +7.6%, RECN +6.8%, URBN +6%, GPN +5.8%, SMRT +5%, ISIS +4.5%, ZUMZ +3.3%, (reports Dec same store sales +8.0% vs +3.9% Retail Metrics consensus; raises Q4 EPS and revs guidance), CATO +2.8%, GALE +2%, PCRX +1.5%, COST +0.5%
Select oil/gas related names showing strength: PBR +3.1%, SDRL +2.3%, TOT +1.9%, BP +1.7%, STO +1.3%, RIG +1.1%, HAL +0.9%
Other news: BIND +49.5% (provides clinical update for BIND-014 and 2015 Strategic Overview; Achieved development milestone as part of the Pfizer collaboration), BIOD +42.1% ( announces positive preliminary results from Study 3-151; data demonstrate That BIOD-531 provides superior glucose control compared to Humalog Mix 75/25 and Humulin(R) R U-500), ACUR +23.2% (partners with Egalet (EGLT) to commercialize immediate release oxycodone product utilizing acura's aversion), CYRN +19.8% (announced that Reliable Networks is the latest UK reseller under distributor VCW Security to offer the cloud-based CYREN WebSecurity solution), NRX +16.7% (has received positive Scientific Advice from the EMA regarding its Phase 3 program with Pyridorin in diabetic nephropathy that has been accepted by the FDA under a Special Protocol Assessment ), STXS +16.3% (co and and Tucson Medical Center announced that they have teamed up to bring the first Stereotaxis Vdrive robotic navigation system with V-Loop variable loop catheter manipulator to the U.S.), VLCCF +14.5% (announced entry into an agreement with RWE Supply & Trading for chartering out a total of 15 Capesize vessels on long term contracts), PLX +9.6% (reports positive interim data from Phase I/II clinical trial of PRX-102 for the treatment of fabry disease), FOLD +8.7% (announces positive Phase 3 data on cardiac endpoints from Fabry Monotherapy study 011 and long term extension study), MNKD +6.2% (earns $50 mln in milestone payments from Sanofi (SNY) ), S +4.7% (reports key preliminary customer results for Q3 including total net additions of nearly 1 mln ), COSI +4.2% (cont strenght follow yday's run up, positive Dec comps), HABT +4.1% ( announces international franchise agreement with Food Quest), RARE +4.1% ( announces license of intellectual property related to the treatment of Huntington's Disease with Triheptanoin ),MERU +3.1% (Vertex Special Opportunities Fund files amended 13D; Believe retention of Deutsche Bank was a step in the right direction), KNDI +2.5% (eer Geely reported sales update; Dec sales volume reached 54,962 units, sales volume down 10% yoy), NVS +2.1% (announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to FDA), GSK +2.1% (may be trading higher in sympathy with peers), BIIB +2.1% ( postive top-line results from Phase 2 Anti-LINGO-1 trial in people with acute optic neuritis), HRB +1.9% (favorable commentary on Wednesday's Mad Money), SUNE +1.9% (purchases new turbines that will enable it to develop up to 1.6 gigawatts of incremental wind energy projects which qualify for the U.S. federal production tax credit), BALT +1.4% (enters into new $148 mln credit facility; Co has taken delivery of the Baltic Wasp)
Analyst comments: WEN +2.4% (upgraded to Equal-Weight from Underweight at Morgan Stanley), BSX +2.1% (upgraded to Outperform from Mkt Perform at Leerink Partners), ALU +1.8% (upgraded to Outperform from Neutral at Credit Suisse), GBX +1.6% (upgraded to Buy from Hold at Stifel), CMI +1.5% (upgraded to Buy from Neutral at BofA/Merrill ), ZU +1.4% (initiated with a Buy at Stifel), OCR +1.3% (upgraded to Overweight from Equal Weight at Barclays), BAC +1.1% (initiated with an Outperform at Credit Suisse), JPM +0.9% (initiated with an Outperform at Credit Suisse), WFC +0.8% (initiated with an Outperform at Credit Suisse), RIO +0.7% (upgraded to Sector Perform at CIBC)
In reaction to strong earnings/guidance/SSS: MG +16%, EXFO +9.1%, (also announces issuer bid to purchase for cancellation up to 7,142,857 subordinate voting shares for an aggregate purchase price not to exceed C$30,000,000), PIR +8.5%, CONN +7.6%, RECN +6.8%, URBN +6%, GPN +5.8%, SMRT +5%, ISIS +4.5%, ZUMZ +3.3%, (reports Dec same store sales +8.0% vs +3.9% Retail Metrics consensus; raises Q4 EPS and revs guidance), CATO +2.8%, GALE +2%, PCRX +1.5%, COST +0.5%
Select oil/gas related names showing strength: PBR +3.1%, SDRL +2.3%, TOT +1.9%, BP +1.7%, STO +1.3%, RIG +1.1%, HAL +0.9%
Other news: BIND +49.5% (provides clinical update for BIND-014 and 2015 Strategic Overview; Achieved development milestone as part of the Pfizer collaboration), BIOD +42.1% ( announces positive preliminary results from Study 3-151; data demonstrate That BIOD-531 provides superior glucose control compared to Humalog Mix 75/25 and Humulin(R) R U-500), ACUR +23.2% (partners with Egalet (EGLT) to commercialize immediate release oxycodone product utilizing acura's aversion), CYRN +19.8% (announced that Reliable Networks is the latest UK reseller under distributor VCW Security to offer the cloud-based CYREN WebSecurity solution), NRX +16.7% (has received positive Scientific Advice from the EMA regarding its Phase 3 program with Pyridorin in diabetic nephropathy that has been accepted by the FDA under a Special Protocol Assessment ), STXS +16.3% (co and and Tucson Medical Center announced that they have teamed up to bring the first Stereotaxis Vdrive robotic navigation system with V-Loop variable loop catheter manipulator to the U.S.), VLCCF +14.5% (announced entry into an agreement with RWE Supply & Trading for chartering out a total of 15 Capesize vessels on long term contracts), PLX +9.6% (reports positive interim data from Phase I/II clinical trial of PRX-102 for the treatment of fabry disease), FOLD +8.7% (announces positive Phase 3 data on cardiac endpoints from Fabry Monotherapy study 011 and long term extension study), MNKD +6.2% (earns $50 mln in milestone payments from Sanofi (SNY) ), S +4.7% (reports key preliminary customer results for Q3 including total net additions of nearly 1 mln ), COSI +4.2% (cont strenght follow yday's run up, positive Dec comps), HABT +4.1% ( announces international franchise agreement with Food Quest), RARE +4.1% ( announces license of intellectual property related to the treatment of Huntington's Disease with Triheptanoin ),MERU +3.1% (Vertex Special Opportunities Fund files amended 13D; Believe retention of Deutsche Bank was a step in the right direction), KNDI +2.5% (eer Geely reported sales update; Dec sales volume reached 54,962 units, sales volume down 10% yoy), NVS +2.1% (announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to FDA), GSK +2.1% (may be trading higher in sympathy with peers), BIIB +2.1% ( postive top-line results from Phase 2 Anti-LINGO-1 trial in people with acute optic neuritis), HRB +1.9% (favorable commentary on Wednesday's Mad Money), SUNE +1.9% (purchases new turbines that will enable it to develop up to 1.6 gigawatts of incremental wind energy projects which qualify for the U.S. federal production tax credit), BALT +1.4% (enters into new $148 mln credit facility; Co has taken delivery of the Baltic Wasp)
Analyst comments: WEN +2.4% (upgraded to Equal-Weight from Underweight at Morgan Stanley), BSX +2.1% (upgraded to Outperform from Mkt Perform at Leerink Partners), ALU +1.8% (upgraded to Outperform from Neutral at Credit Suisse), GBX +1.6% (upgraded to Buy from Hold at Stifel), CMI +1.5% (upgraded to Buy from Neutral at BofA/Merrill ), ZU +1.4% (initiated with a Buy at Stifel), OCR +1.3% (upgraded to Overweight from Equal Weight at Barclays), BAC +1.1% (initiated with an Outperform at Credit Suisse), JPM +0.9% (initiated with an Outperform at Credit Suisse), WFC +0.8% (initiated with an Outperform at Credit Suisse), RIO +0.7% (upgraded to Sector Perform at CIBC)